Opening soon. Stay in the loop

goodmorrowJoin the opening list

Tesamorelin, explained.

Egrifta. Research, safety questions, and treatment context.

Updated Clinical review pending · Educational draft

The form

Preparation matters

The routine

No personal schedule is set by this guide.

The evidence

See the evidence and source notes below.

Research, approval and availability are separate questions.

Legal status
FDA-approved drug

FDA-approved as Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Prescribing it for other patients is off-label.

At Goodmorrow
Offered when we open

What it is

Tesamorelin is a modified version of growth hormone releasing hormone. The FDA approved it in 2010 to reduce excess abdominal fat in adults with HIV who develop lipodystrophy. A newer formulation, Egrifta WR, was approved in 2025.

What the evidence shows

In the trials behind its approval, tesamorelin reduced visceral fat compared with placebo over 26 weeks. The fat tended to come back after people stopped.

Those trials were in people with HIV. Using it for other patients is off-label, which is legal and common, but the evidence outside that group is weaker.

How Goodmorrow handles it

We prescribe brand-name tesamorelin. Compounded versions copy a drug that's commercially available, which puts them in the same legal position as compounded semaglutide, so we don't use them.

Before you take it

  • Tesamorelin medication is an additional self-pay cost. We will confirm the price before you decide.
  • It can raise blood sugar, so we check glucose and IGF-1 along the way.

Stacks that include it

  • GLP-1 Plus: our program for what the medication doesn't fix on its own

Questions people ask

Can I take tesamorelin with Zepbound or Wegovy?

Yes, and that's the main reason we offer it. GLP-1 medication drives overall weight loss; tesamorelin targets the visceral fat that sometimes lags behind. Your clinician will check your labs first.

Sources

  1. FDA documentEgrifta SV (tesamorelin) prescribing information U.S. Food and Drug Administration
  2. Secondary sourceFDA Approves Egrifta WR to Treat Excess Visceral Abdominal Fat in Adults With HIV Pharmacy Practice News, March 2025

Good days ahead.

Join the opening list for appointment updates.

Join the opening list